Addievi Amper
Nurse Practitioner · Mission, TXNPI 1346671401
Payments from drug & device makers
Across 22 payments — averaging $103.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$353
- Otsuka America Pharmaceutical, Inc.$350
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
- Teva Pharmaceuticals USA, Inc.$312
- AstraZeneca$222
- Melinta Therapeutics, LLC$125
- plus $569 from 5 others
What the payments were for
- Food & beverage$2,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 3 | $353 |
| Otsuka America Pharmaceutical, Inc. | 3 | $350 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $340 |
| Teva Pharmaceuticals USA, Inc. | 3 | $312 |
| AstraZeneca(2 entities) | 3 | $222 |
| Melinta Therapeutics, LLC | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $124 |
| Ironshore Pharmaceuticals Inc. | 2 | $118 |
| Corium, LLC | 1 | $115 |
| Lilly USA, LLC | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$955
- LYBALVI$457
- CAPLYTA$253
- ARISTADA INITIO$239
- Austedo XR$229
- LOKELMA$207
- ABILIFY MAINTENA$128
- ABILIFY ASIMTUFII$128
- Fanapt$125
- Rezzayo$125
- REXULTI$124
- NUZYRA$124
- Azstarys$115
How this compares
$2,271 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 58 | $472 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $286 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $124 |
| Naproxen | 41 | $120 |
| Meclizine Hcl | 14 | $95 |
| Ondansetron Hcl | 19 | $62 |
| Azithromycin | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Mission
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
- Onna FeuchterSouthlake$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.